ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Clinical insights into the association between chronic liver disease and osteoporosis.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a common complication among children with chronic liver disease (CLD) and cholestasis. This condition is multifactorial, as many different liver dysfunction-related mechanisms contribute to bone loss. The overall prevalence of osteoporosis in patients with advanced CLD ranges from 12% to more than 55%. Patients with CLD have a 2- to 4-fold higher risk of hip, vertebral, and nonvertebral fractures than do matched healthy individuals. Vertebral fractures are particularly common, often occurring in 20% to 30% of cirrhotic patients, even in those whose bone mineral density scores do not strictly meet the osteoporosis threshold. Research in this field has focused primarily on bone health in patients with chronic cholestatic liver diseases, particularly primary biliary cholangitis, before and after liver transplantation. However, studies on bone and mineral disorders associated with other liver diseases, such as viral hepatitis, nonalcoholic fatty liver disease, hemochromatosis, Wilson's disease, and alcoholic liver disease, are rare. Many factors, including impaired bone formation, increased bone resorption, vitamin D deficiency, sex hormone deficiency, nutritional deficiency, and alcohol toxicity contribute to the accurate diagnosis of bone disorders, most commonly osteomalacia and osteoporosis, but they also result in management dilemmas. The management of bone complications in patients with cholestatic and advanced forms of liver disease can be challenging because treatment requires establishing the underlying cause and promoting bone health by increasing bone formation. In many clinics, physicians encounter challenging cases of vertebral fractures because approximately one-third of vertebral fractures are asymptomatic. Therefore, identifying the cause of unknown bone complications in children with CLD is challenging. Thus, this review discusses the association between chronic liver disease and osteoporosis in children.
Indexed as
Identifiers
42440081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.